MDT — Medtronic plc

Sentiment has clearly improved since the September 1, 2026 fiscal Q1 2027 print (filed 2026-09-03), in which revenue rose ~9.9% YoY to roughly $9.8B and management raised full-year FY27 EPS guidance to $5.94-$6.00. Sell-side targets have been marked up (Needham to $114, TD Cowen and Citi to $110), the consensus sits at Buy/Moderate Buy with an average target near $98-$101 (vs. the $90.96 close on 2026-09-13), and the shares returned +13.42% over the trailing three months. It is bullish, not euphoric: RSI was a neutral 51.6 on 2026-09-13, the stock was 1.13% below its 20-day average and down 3.41% on the week, and 20 of 51 ratings tracked in the FMP breakdown are still Holds, meaning the market is paying only ~15x forward adjusted earnings for a beat-and-raise story.

The trend is genuine acceleration, not a blip. Year-over-year revenue growth bottomed at +2.5% in the quarter ended 2025-01-24 and has climbed every reporting period since: +3.9% (2025-04-25), +8.4% (2025-07-25), +6.6% (2025-10-24), +8.8% (2026-01-23), +9.9% (2026-04-24), and +13.7% (2026-07-31, $9.756B vs. $8.578B). Operating margin has also recovered from a depressed 12.3% in the quarter ended 2024-04-26 to 18.1% in the latest quarter, up roughly 130bp YoY versus 16.8% in the year-ago period, with the two most recent January quarters running near 19.7-19.8%. Trailing-twelve-month GAAP EPS of $4.06 is up ~11.8% from $3.63 a year earlier, and TTM free cash flow of $6.13B is up ~15.6% from $5.30B (quarterly FCF of $1.29B in Jul-2026 more than doubled the $584M generated a year earlier). Balance-sheet quality is stable: stockholders' equity grew from $47.9B (2025-07-25) to $50.2B (2026-07-31) while long-term debt stayed roughly flat near $25.6B. Two caveats worth flagging: the quarter ended 2026-04-24 shows a gross margin of 75.9% versus the ~60-67% norm, which looks like a one-off item rather than a step-change; and Q1 FY27 revenue of $9.756B was essentially flat sequentially versus $9.807B, so part of the headline YoY gain reflects an easy comparison and possibly an extra selling week. The direction is nonetheless up and the drivers (Cardiac Ablation Solutions, Affera, Symplicity Spyral) are procedure-driven rather than one-time.

Cheap versus its own history, and cheap versus its peer group on adjusted earnings. As of 2026-09-13 the price of $90.96 put MDT at 22.24x TTM GAAP EPS versus a 5-year average P/E of 26.83x (roughly a 17% discount), at 3.10x TTM sales versus a 5-year average of 3.55x (about a 13% discount), at 2.32x book, and at a PEG of 1.755 on trailing numbers. On forward figures it is more striking: the FY27 adjusted EPS midpoint of $5.975 (analyst average $5.975, guidance $5.94-$6.00) implies ~15.2x forward earnings, roughly 30-40% below where large-cap medtech peers typically trade. EV/EBITDA of ~15.2x and a 3.52% dividend yield round out a value-plus-income profile. The honest caveat: TTM GAAP EPS of $4.087 already lags adjusted earnings because of intangible amortization, restructuring and litigation charges, so the headline 'cheap' is partly optical, and an ROIC of just 6.1% means the market may be discounting a real return-on-capital problem rather than simply overlooking the stock.

At $90.96 the market is paying 15.2x FY27 adjusted EPS of $5.975 but 22.2x the $4.087 of GAAP EPS actually delivered over the past twelve months - the whole bull case hinges on that gap closing. The price is crediting the revenue acceleration and the raised guidance only partially: if Medtronic merely lands at the low end of guidance ($5.94) the multiple compresses further, and if high-single-digit top-line growth holds with margin expansion, the current multiple is too low for a 3.5%-yielding defensive medtech. The bear reading is that the +13.7% YoY quarter was flattered and the GAAP-to-adjusted conversion does not improve, in which case today's price is a full 22x on real earnings with a dividend payout of ~71% of GAAP EPS (though only ~48% of forward adjusted EPS and ~61% of TTM free cash flow). Practical implication: the stock is being priced as a low-growth recovery, so a re-rating depends less on the next EPS beat and more on proof that organic growth above 8% and stable-to-rising operating margins are durable into FY28.

As of 2026-09-13, RSI(14) stood at 51.57 - squarely neutral with no overbought or oversold signal. The $90.96 close was 1.13% below the 20-day SMA (implied ~$92.00), 3.73% above the 50-day SMA (implied ~$87.70), and 1.58% above the 200-day SMA (implied ~$89.55), a mild pullback inside a still-intact uptrend. Momentum is mixed by horizon: +13.42% over three months and +4.38% over six months, but -3.41% over the past week and just +0.22% over one month. The 52-week range of $73.31-$106.33 puts the shares slightly above the midpoint of that band. Read: range-bound to modestly uptrending; the recent dip is a normal pause after a strong three-month run, not a breakdown. There is no oversold signal to buy, so the better entry discipline would be a pullback toward the 50-day area (~$87-88), while a decisive close back above the 20-day would confirm the uptrend resumed.

• Interest rates and inflation: with a beta of just 0.574 and a 3.52% dividend, MDT behaves as a defensive haven when risk-off rotations hit healthcare, but lingering hot PCE prints and shifting rate expectations periodically pressure all long-duration medical-device multiples.
• Elective procedure volumes: solid hospital demand underpins Cardiovascular and Medical Surgical; a slowdown in elective procedures or hospital capital budgets would hit the procedure-driven growth that is currently the whole thesis.
• MedTech competitive intensity: pulsed-field ablation (Affera/Sphere-9 vs. Boston Scientific and J&J) and robotic surgery (Hugo, plus the August 31, 2026 Cornerstone Robotics partnership) are contested, high-stakes markets where share shifts can reverse a growth narrative quickly.
• Input costs and supply chain: persistent cost pressure and supply friction are explicitly called out as limiting margin expansion, and device manufacturing is exposed to tariff and freight volatility.
• Regulatory and litigation environment: device approval/recall risk plus ongoing liability matters (including an $88M jury verdict related to a Covidien hernia-mesh case) create headline and cash-cost risk that is not visible in the headline multiples.

• Fiscal Q2 2027 earnings in late November/early December 2026 - the first real test of whether cardiovascular momentum (Cardiac Ablation Solutions, Affera, Symplicity Spyral) can offset softer segments and validate the raised FY27 EPS guidance of $5.94-$6.00.
• Separation or exit of the Diabetes division targeted for late 2027 - removes a lower-margin drag and could narrow MDT's valuation discount to higher-multiple medtech peers as milestones are announced.
• Commercial and clinical milestones on Hugo robotic surgery and the August 31, 2026 Cornerstone Robotics partnership, plus management commentary at the Wells Fargo Healthcare Conference in September 2026.
• Achievement of 'Dividend King' status (50 consecutive annual increases) expected by mid-2027, following the $0.72 quarterly dividend declared on August 20, 2026 - a catalyst for income-focused institutional flows.

• Return on invested capital of just 6.1% (with ROE of 9.7%) is below a plausible cost of capital - if accelerating revenue does not convert into better returns on capital, the low forward multiple is deserved rather than a bargain, which is the classic value-trap setup here.
• GAAP earnings quality and the adjusted-earnings gap: TTM GAAP EPS is $4.087 versus ~$5.975 of forward adjusted EPS, so the entire cheapness argument rests on non-GAAP numbers; amortization and litigation continue to suppress GAAP EPS and leave the dividend at ~71% of GAAP earnings.
• Durability of the growth inflection: the latest quarter's +13.7% YoY growth came against an easy comparison and a sequential revenue decline ($9.807B to $9.756B); a reversion toward low-single-digit growth would unwind the re-rating.
• Competitive pressure in pulsed-field ablation and robotic surgery from better-capitalized or more deeply entrenched rivals, which could cap both share gains and pricing.
• Execution risk on the Diabetes separation, including dis-synergies and stranded costs, plus the drag of ~$25.6B long-term debt against only $1.69B of cash, which limits large-scale M&A flexibility.

Medtronic is a genuinely defensible value-plus-income holding right now, not a high-conviction growth compounder. The good news is real and measurable: revenue growth has inflected from +2.5% YoY in the January 2025 quarter to +13.7% in the July 2026 quarter, operating margin has climbed from 12.3% to 18.1%, TTM free cash flow of $6.13B covers the 3.52% dividend roughly 1.6x, and the stock trades at ~15.2x forward adjusted EPS and about 13% below its own five-year average price/sales. The bad news is equally real: ROIC of 6.1% is below any reasonable cost of capital, the cheap forward multiple depends on non-GAAP earnings that run roughly $1.90/share above GAAP, and the latest quarter's growth was partly flattered by an easy comparison. For a patient investor willing to underwrite low-single-digit-plus total return with a rising dividend while the CAS/Hugo/renal-denervation portfolio matures, the risk/reward skews favorably; the stock is not priced for that success, and a modest pullback toward the 50-day average would improve the entry.

Two independent methods converge on ~$104 as of 2026-09-13. First, applying a 17.5x multiple to the FY27 adjusted EPS midpoint of $5.975 (management guidance $5.94-$6.00, analyst average $5.975) yields $104.6; that multiple is a deliberate discount to the ~20-25x large-cap medtech peer group and to MDT's own 26.83x five-year average P/E on trailing GAAP earnings. Second, reverting the shares to their own five-year average price/sales of 3.55x from the current 3.10x on $37.54B of TTM revenue (equivalently, $90.96 x 3.55/3.10) gives $104.1 using ~1.289B shares outstanding. The discount to peers and to history is justified by sub-cost-of-capital ROIC of 6.1% and the GAAP-to-adjusted earnings gap, while the accelerating revenue trend, recovering operating margin and 3.52% dividend argue against a larger discount.